These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32452998)

  • 1. Treatment of the primary in metastatic prostate cancer.
    Gîngu C; Heidenreich A; Andreşanu A; Mihancea A; Sinescu I; Baston C
    Curr Opin Urol; 2020 Jul; 30(4):566-575. PubMed ID: 32452998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.
    Bayne CE; Williams SB; Cooperberg MR; Gleave ME; Graefen M; Montorsi F; Novara G; Smaldone MC; Sooriakumaran P; Wiklund PN; Chapin BF
    Eur Urol; 2016 May; 69(5):775-87. PubMed ID: 26003223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncologic role of local treatment in primary metastatic prostate cancer.
    Ghadjar P; Briganti A; De Visschere PJ; Fütterer JJ; Giannarini G; Isbarn H; Ost P; Sooriakumaran P; Surcel CI; van den Bergh RC; van Oort IM; Yossepowitch O; Ploussard G
    World J Urol; 2015 Jun; 33(6):755-61. PubMed ID: 24997127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate radiotherapy in newly diagnosed metastatic prostate cancer.
    Ali A; Parker CC; Clarke NW
    Curr Opin Urol; 2019 Nov; 29(6):620-628. PubMed ID: 31584887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
    Ranasinghe WKB; Reichard CA; Chapin BF
    Eur Urol; 2019 Nov; 76(5):543-545. PubMed ID: 31248604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?
    Morgan SC; Dearnaley DP
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):939-51. PubMed ID: 19589033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the management of high-risk localised and metastatic prostate cancer.
    Bellmunt J; Attard G; Bahl A; Huland H; Klotz L; Kuban D; Oudard S; Watson W
    BJU Int; 2012 Mar; 109 Suppl 2():8-13. PubMed ID: 22257099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial.
    Abdel-Rahman O; Cheung WY
    Clin Genitourin Cancer; 2018 Dec; 16(6):466-472. PubMed ID: 30098982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.
    Sonpavde G; Palapattu GS
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):439-50. PubMed ID: 20214524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy after radical prostatectomy: clinical considerations.
    Mitra A; Khoo V
    Surg Oncol; 2009 Sep; 18(3):247-54. PubMed ID: 19285386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant and adjuvant treatment in high-risk prostate cancer.
    Bandini M; Fossati N; Gandaglia G; Preisser F; Dell'Oglio P; Zaffuto E; Stabile A; Gallina A; Suardi N; Shariat SF; Montorsi F; Karakiewicz PI; Briganti A
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):425-438. PubMed ID: 29355037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cytoreductive radical prostatectomy in metastatic prostate cancer.
    Vladimír Š; Zuzana S; Hana Š
    Klin Onkol; 2022; 35(1):55-62. PubMed ID: 35236082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
    Weiner AB; Nettey OS; Morgans AK
    Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different therapeutic regimens in the treatment of metastatic prostate cancer by performing a Bayesian network meta-analysis.
    Zhang Q; Cheng H; Wang Y; Tian Y; Xia J; Wang Y; Zhou X; Meng X; Wang Y; Gu M; Song N
    Int J Surg; 2019 Jun; 66():28-36. PubMed ID: 31002882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of radical prostatectomy in metastatic prostate cancer: A review.
    Metcalfe MJ; Smaldone MC; Lin DW; Aparicio AM; Chapin BF
    Urol Oncol; 2017 Apr; 35(4):125-134. PubMed ID: 28190749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
    Kim J; Park JS; Ham WS
    Investig Clin Urol; 2017 Sep; 58(5):307-316. PubMed ID: 28868501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.